Canrenone as Add-on in Patients With Essential Hypertension
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy on blood pressure reduction, safety and tolerability of two
different dosages of canrenone as add-on therapy in patients already treated with Angiotensin
Converting-Enzyme Inhibitors (ACE-I) or Angiotensin II Receptor Blockers (ARBs) and diuretics
at the maximum dosage.